Neuren Pharmaceuticals Limited · ASX:NEU

Neuren Pharmaceuticals — Shareholder Meeting (May 2005)

17 slides from Neuren Pharmaceuticals's shareholder meeting presentation, May 30, 2005

  1. Slide 1: Neuren Pharmaceuticals AGM cover letter

    Neuren Pharmaceuticals Ltd Level 3, 2-6 Park Avenue, Grafton Nl e U Te | | Auckland, New Zealand office: +64 9 367 7167 fax: +64 9 367 7186 enquiry@neurenpharma.com pharma ceuti cals www.neurenpharma.com 30 May 2005 The Company Announcements Office Australian Stock Exchange Limited BY E-LODGEMENT De

  2. Slide 2: Neuren

    neuren

  3. Slide 3: Partnerships and board and management strengthening

    aan Ee ene A oN ERNE RNIM + Partnership ~« US Army ~ + Metabolic - Board and Management Strengthens neuren x _ — oa

  4. Slide 4: nim

    ae i 7 vn nim zy IN iii i nnn 2) i) i i il #2) a a eed

  5. Slide 5: Metabolic Syndrome / Breast Cancer

    Metabolic Syndrome Breast Cancer neuren

  6. Slide 6: NNZ-2566 (oral)

    * NNZ-2566 (oral) cme iy - DKP’s +MC’s *NRP’s + GH Cancer + GH Variants neuren

  7. Slide 7: i ala

    an i ala i} | niversity of Hou <<. os ng Potentia neuren

  8. Slide 8: Phase on target, manufacturing finalised

    LN ce au ot Wunte nn LNAI nn a na ii - Phase 1 on target . - Manufacturing Finalised and Cost Effec - Tox Study Supplier Selected neuren : _—rrrr—_—Cii_COC

  9. Slide 9: Brain injury drug with US arm

    a LL. pi iin on AM i) MM) J i i «Additional work with US arm e / 8 7 « “Goal... advanced drug for brain inju y”

  10. Slide 10: Government grant and MBP peptide chemistry

    nent iH ao NAM i Mi Ni fD — i a dependent v. * Government Grant AS585 e Utilise MBP Peptide Chemistry S neuren ie

  11. Slide 11: TTT TTC Te

    TTT TTC Te a lt TG I ee CCl a i lil neuren “ Lees a ag Se

  12. Slide 12: Clinical Development Experience

    Slinical Development Experience ¢ Rob Turnbull, | private B P a * Prof. Stan Newman neuren “a — oo

  13. Slide 13: fy ai

    fy ai Wh a BA Ss i elie 7 Raum a enor positior ions in healthcar ), Sout esi i Ih ae neuren — ae .

  14. Slide 14: nnn eae

    nnn eae i) i) SM itn iM neuren : | ~

  15. Slide 15: wan

    wan neuren < — a

  16. Slide 16: Robust and focused drug development

    RNG Oe BI) - INC includ the pi ther science — Robust and focused drug development neuren oo a .

  17. Slide 17: Neuren

    neuren SE neuren : ee eo a:

Neuren Pharmaceuticals — Shareholder Meeting (May 2005) on 6ix